|
p16-INK4A
a cell-cycle regulatory protein that interacts with CDK4 and CDK6, inhibiting their ability to interact with cyclins D. Inhibits the phosphorylation of the retinoblastoma protein by CDK4 or CDK6, and entry into the S phase of the cell cycle. The p16INK4A and p14ARF proteins are encoded by CDKN2A, a known tumour suppressor gene in multiple cancers. CDKN2A is inactivated in 72% of cases of lung squamous cell carcinoma: 21% by epigenetic silencing by methylation, 18% inactivating mutation, 4% by exon 1b skipping, and 29% by homozygous deletion. Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome, Li-Fraumeni syndrome, and the melanoma-astrocytoma syndrome. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Four alternatively spliced p16 isoforms have been reported. Two alternatively spliced isoforms of ARF have been reported. Note: This description may include information from UniProtKB.
|
| Protein type: Cell cycle regulation |
|
Cellular Component: nucleoplasm; nuclear body; protein complex; cytoplasm; nucleolus; cytosol; nucleus
|
|
Molecular Function: cyclin-dependent protein kinase inhibitor activity; NF-kappaB binding; protein binding; DNA binding; p53 binding; ubiquitin-protein ligase inhibitor activity; transcription factor activity; protein kinase binding; transcription factor binding
|
|
Biological Process: epidermis development; protein polyubiquitination; somatic stem cell maintenance; positive regulation of transcription, DNA-dependent; positive regulation of apoptosis involved in mammary gland involution; regulation of protein stability; negative regulation of B cell proliferation; regulation of protein export from nucleus; negative regulation of cell proliferation; apoptotic mitochondrial changes; regulation of G2/M transition of mitotic cell cycle; somatic stem cell division; DNA fragmentation during apoptosis; G1 phase of mitotic cell cycle; cell cycle arrest; negative regulation of immature T cell proliferation in the thymus; caspase activation; protein destabilization; transcription, DNA-dependent; protein stabilization; negative regulation of cyclin-dependent protein kinase activity; negative regulation of cell-matrix adhesion; negative regulation of mammary gland epithelial cell proliferation; rRNA transcription; positive regulation of protein sumoylation; inhibition of NF-kappaB transcription factor; regulation of nucleocytoplasmic transport; induction of apoptosis; Ras protein signal transduction; negative regulation of ubiquitin-protein ligase activity; negative regulation of protein kinase activity; negative regulation of phosphorylation; positive regulation of transcription from RNA polymerase II promoter; mitotic cell cycle; negative regulation of cell growth; positive regulation of DNA damage response, signal transduction by p53 class mediator; negative regulation of transcription, DNA-dependent; cell cycle checkpoint; rRNA processing; G1/S transition of mitotic cell cycle
|
|
Reference #:
P42771 (UniProtKB)
|
| Alt. Names/Synonyms: ARF; CD2A1; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; CDKN2A; cell cycle negative regulator beta; CMM2; Cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A, isoform 4; Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3; cyclin-dependent kinase inhibitor p16; INK4; INK4a; MLM; MTS-1; MTS1; Multiple tumor suppressor 1; p14; p14ARF; p16; p16-INK4; p16-INK4a; p16INK4; p16INK4A; p19; p19Arf; TP16 |
| Gene Symbols: CDKN2A |
|
Molecular weight: 16,533 Da
|
|
Basal Isoelectric point: 5.52
Predict pI for various phosphorylation states
|
|
CST Pathways:
Cell Cycle: G1/S Checkpoint
|
Protein-Specific Antibodies or siRNAs from Cell Signaling Technology®
|
